What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2022-08-15 compared with 2022-05-20 · 756 added, 478 removed, 496 unchanged (71% of the section changed)

1 unchanged sentence

quarterly report on Form 10-Q (the “Report”) of Digital Ally, Inc.

(the “Company”, “we”, “us”,

or “our”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,”

“should,” “could,” “will,” “plan,” “future,” “continue,” and

other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify

forward-looking statements.

These forward-looking statements are based largely on our expectations or forecasts of future events, can

be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which

are beyond our control.

Therefore, actual results could differ materially from the forward-looking statements contained in this document,

and readers are cautioned not to place undue reliance on such forward-looking statements.

undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events

or otherwise.

A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability,

cash flows and capital needs.

There can be no assurance that the forward-looking statements contained in this document will, in fact,

transpire or prove to be accurate.

that could cause or contribute to our actual results differing materially from those discussed herein or for our stock price to be adversely

affected include, but are not limited to:

(the “Company”, “we”,

“us”, or “our”) contains forward-looking statements within the meaning of Section 27A of the Securities Act

of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

“aim,” “anticipate,” “believe,” “continue,” “could,”

“estimate,” “expect,” “feel,” “forecast,” “intend,” “may,”

“outlook,” “plan,” “potential,” “predict,” “project,”

“seek,” “should,” “will,” “would,” and similar expressions intended to identify

forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking

statements are based largely on our expectations or forecasts of future events, can be affected by inaccurate assumptions, and are

subject to various business risks and known and unknown uncertainties, a number of which are beyond our control.

Therefore, actual

results could differ materially from the forward-looking statements contained in this document, and readers are cautioned not to

place undue reliance on such forward-looking statements.

undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future

events or otherwise.

A variety of factors could cause or contribute to such differences and could adversely impact revenues,

profitability, cash flows and capital needs.

There can be no assurance that the forward-looking statements contained in this

document will, in fact, transpire or prove to be accurate.

Factors that could cause or contribute

to our actual results differing materially from those discussed herein or for our stock price to be adversely affected include, but are

not limited to:

(1) our losses in recent years, including during fiscal 2020 and 2019;

(2) economic and other

risks for our business from the effects of the COVID-19 pandemic, including the impacts on our law-enforcement and commercial customers,

suppliers and employees and on our ability to raise capital as required;

(3) our ability to increase revenues, increase our margins and

return to consistent profitability in the current economic and competitive environment;

(4) our operation in developing markets and uncertainty

as to market acceptance of our technology and new products;

(5) the availability of funding from federal, state and local governments

to facilitate the budgets of law enforcement agencies, including the timing, amount and restrictions on such funding;

(6) our ability

to deliver our new product offerings, such as the Shield™ disinfectant/sanitizers products and ThermoVU™ temperature screening

systems, whether such new products perform as planned or advertised and whether they will help increase our revenues, particularly

as the COVID-19 pandemic begins to subside;

(7) whether we will be able to increase the sales, domestically and internationally,

for our products in the future;

(8) our ability to maintain or expand our share of the market for our products in the domestic and international

markets in which we compete, including increasing our international revenues;

(9) our ability to produce our products in a cost-effective

(10) competition from larger, more established companies with far greater economic and human resources;

(11) our ability to attract

and retain quality employees;

(12) risks related to dealing with governmental entities as customers;

(13) our expenditure of significant

resources in anticipation of sales due to our lengthy sales cycle and the potential to receive no revenue in return;

(14) characterization

of our market by new products and rapid technological change;

(15) our dependence on sales of our EVO-HD, DVM-800, DVM-250 and FirstVU

(16) that stockholders may lose all or part of their investment if we are unable to compete in our markets and return to profitability;

(17) defects in our products that could impair our ability to sell our products or could result in litigation and other significant costs;

(18) our dependence on key personnel;

(19) our reliance on third-party distributors and sales representatives for part of our marketing

(20) our dependence on a few manufacturers and suppliers for components of our products and our dependence on domestic and

foreign manufacturers for certain of our products;

(21) our ability to protect technology through patents and to protect our proprietary

technology and information, such as trade secrets, through other similar means;

(22) our ability to generate more recurring cloud and

service revenues;

(2) economic and other risks for our business from

the effects of the COVID-19 pandemic, including the impacts on our law-enforcement and commercial customers, suppliers and employees and

on our ability to raise capital as required;

(3) our ability to increase revenues, increase our margins and return to consistent profitability

in the current economic and competitive environment;

(4) our operation in developing markets and uncertainty as to market acceptance of

our technology and new products;

(5) the availability of funding from federal, state and local governments to facilitate the budgets of

law enforcement agencies, including the timing, amount and restrictions on such funding;

(6) our ability to maintain or expand our share

of the market for our products in the domestic and international markets in which we compete, including increasing our international revenues;

(7) our ability to produce our products in a cost-effective manner;

(8) competition from larger, more established companies with far greater

economic and human resources;

(9) our ability to attract and retain quality employees;

(10) risks related to dealing with governmental

entities as customers;

(11) our expenditure of significant resources in anticipation of sales due to our lengthy sales cycle and the potential

to receive no revenue in return;

(12) characterization of our market by new products and rapid technological change;

(13) our dependence

on sales of our EVO-HD, DVM-800, DVM-250 and FirstVU products;

(14) that stockholders may lose all or part of their investment if we are

unable to compete in our markets and return to profitability;

(15) defects in our products that could impair our ability to sell our products

or could result in litigation and other significant costs;

(16) our dependence on a few manufacturers and suppliers for components of

our products and our dependence on domestic and foreign manufacturers for certain of our products;

(17) our ability to protect technology

through patents and to protect our proprietary technology and information, such as trade secrets, through other similar means;

ability to generate more recurring cloud and service revenues;

(19) risks related to our license arrangements;

(24) the fluctuation of our operation results from quarter to

(25) sufficient voting power by coalitions of a few of our larger stockholders, including directors and officers, to make corporate

governance decisions that could have a significant effect on us and the other stockholders;

(26) the issuance or sale of substantial

amounts of our common stock, or the perception that such sales may occur in the future, which may have a depressive effect on

the market price of our securities;

(27) potential dilution from the issuance of common stock underlying outstanding

options and warrants;

(20) the fluctuation of

our operation results from quarter to quarter;

(21) sufficient voting power by coalitions of a few of our larger stockholders, including

directors and officers, to make corporate governance decisions that could have a significant effect on us and the other stockholders;

(22) the issuance or sale of substantial amounts of our common stock, or the perception that such sales may occur in the future, which

may have a depressive effect on the market price of our securities;

(23) potential dilution from the issuance of common stock underlying

outstanding options and warrants;

(24) our additional securities available for issuance, which, if issued, could adversely affect the

rights of the holders of our common stock;

(29) the volatility of our stock price due to a number of factors, including, but

not limited to, a relatively limited public float;

and (30) our ability to integrate and realize the anticipated benefits from

acquisitions.

(25) the volatility of our stock price due to a number of factors, including, but not limited

to, a relatively limited public float;

(26) our ability to integrate and realize the anticipated benefits from acquisitions;

ability to maintain the listing of our common stock on the Nasdaq Capital Market.

Trends and Recent Developments for the Company

9 unchanged sentences

and the FirstVu HD;

our patented and revolutionary VuLink product which integrates our body-worn cameras with our in-car systems

by providing hands-free automatic activation for both law enforcement and commercial markets;

the FLT-250, DVM-250, and DVM-250 Plus,

which are our commercial line of digital video mirrors that serve as “event recorders” for the commercial fleet and mass

transit markets;

our patented and revolutionary VuLink product which integrates our body-worn cameras with our in-car systems by providing

hands-free automatic activation for both law enforcement and commercial markets;

the FLT-250, DVM-250, and DVM-250 Plus, which are our

commercial line of digital video mirrors that serve as “event recorders” for the commercial fleet and mass transit markets;

and FleetVu and VuLink, which are our cloud-based evidence management systems.

We further diversified and broadened

our product offerings in 2020, by introducing two new lines of branded products:

(1) the ThermoVu® which is a line of self-contained

temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set

threshold and (2) our Shield™ disinfectants and cleansers which are for use against viruses and bacteria.

We began offering our

Shield™ disinfectants and cleansers to our law enforcement and commercial customers late in the second quarter of 2020.

Our video solutions

segment revenue encompasses video recording products and services for our law enforcement and commercial customers and the sale of

Shield disinfectant and personal protective products.

This segment generates revenues through our subscription models offering cloud

and warranty solutions, and hardware sales for video and personal protective safety products and solutions.

We further diversified and broadened our product offerings

in 2020, by introducing two new lines of branded products:

(1) the ThermoVu® which is a line of self-contained temperature monitoring

stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2)

our Shield™ disinfectants and cleansers which are for use against viruses and bacteria.

video solutions segment revenue encompasses video recording products and services for our law enforcement and commercial customers and

the sale of Shield disinfectant and personal protective products.

This segment generates revenues through our subscription models offering

cloud and warranty solutions, and hardware sales for video and personal protective safety products and solutions.

Revenues for product

1 unchanged sentence

term of the subscription, typically 3 or 5 years.

To judge the health of our

video solutions segment, we review the current active subscriptions and deferred service revenues, along with the quantity and gross

margins generated by our video solutions hardware sales.

Cycle Management Operating Segment - We have recently entered the revenue cycle management business late in the second quarter of

2021 with the formation of our wholly owned subsidiary, Digital Ally Healthcare, Inc.

and its majority-owned subsidiary Nobility Healthcare.

Nobility Healthcare completed its first acquisition on June 30, 2021, when it acquired a private medical billing company, and a second

acquisition on August 31, 2021 upon the completion of its acquisition of another private medical billing company, along with two more

acquisitions completed during the three months ended March 31, 2022, in which we assist in providing working capital and back-office

services to healthcare organizations throughout the country.

Our assistance consists of insurance and benefit verification, medical treatment

documentation and coding, and collections.

Through our expertise and experience in this field, we maximize our customers’ service

revenues collected, leafing to substantial improvements in their operating margins and cash flows.

Our revenue cycle management

segment consists of our medical billing subsidiaries.

Revenues of this segment are recognized after we perform the obligations of our

revenue cycle management services.

Our revenue cycle management services are services, performed and charged monthly, generally based

on a contractual percentage of total customer collections, for which we recognize our net service fees.

To judge the health of our

revenue cycle management segment, we review the collection success rate and collection timing.

In addition, we review the associated

costs incurred to assist our customers, and any changes in operating margins and cash flows.

Cycle Management Operating Segment - We have recently entered the revenue cycle management business late in the second quarter

of 2021 with the formation of our wholly owned subsidiary, Digital Ally Healthcare, Inc.

and its majority-owned subsidiary Nobility

Nobility Healthcare completed its first acquisition on June 30, 2021, when it acquired a private medical billing

company, and a second acquisition on August 31, 2021 upon the completion of its acquisition of another private medical billing

company, along with two more acquisitions completed during the three months ended March 31, 2022, in which we assist in providing

working capital and back-office services to healthcare organizations throughout the country.

Our assistance consists of insurance

and benefit verification, medical treatment documentation and coding, and collections.

Through our expertise and experience in this

field, we aim to maximize our customers’ service revenues collected, leading to substantial improvements in their operating

margins and cash flows.

revenue cycle management segment consists of our medical billing subsidiaries.

Revenues of this segment are recognized after we perform

the obligations of our revenue cycle management services.

Our revenue cycle management services are services, performed and charged monthly,

generally based on a contractual percentage of total customer collections, for which we recognize our net service fees.

Operating Segment - We have also recently entered into live entertainment and events ticketing services through the formation of

4 unchanged sentences

of events, including concerts, sporting events, theatres, and performing arts, throughout the country.

Our ticketing operating segment

consists of ticketing services provided through TicketSmarter and its online platform, TicketSmarter.com.

Revenues of this segment include

ticketing service charges generally determined as a percentage of the face value of the underlying ticket and ticket sales from our ticket

inventory which are recognized when the underlying tickets are sold.

Ticketing direct expenses include the cost of tickets purchased

for resale by the Company and held as inventory, credit card fees, ticketing platform expenses, website maintenance fees, along with

other administrative costs.

To judge the health of our

ticketing operating segment, we review the gross transaction value, which represents the total value related to a ticket sale and includes

the face value of the ticket as well as the service charge.

In addition, we review the number of visits to our websites, cost of customer

acquisition, the purchase conversion rate, the overall number of customers in our database, and the number and percentage of tickets

sold via the website and mobile app.

ticketing operating segment consists of ticketing services provided through TicketSmarter and its online platform, TicketSmarter.com.

Revenues of this segment include ticketing service charges generally determined as a percentage of the face value of the underlying ticket

and ticket sales from our ticket inventory which are recognized when the underlying tickets are sold.

Ticketing direct expenses include

the cost of tickets purchased for resale by the Company and held as inventory, credit card fees, ticketing platform expenses, website

maintenance fees, along with other administrative costs.

of Operations

financial information for the Company’s reportable business segments is provided for the three months ended March 31, 2022, and

Three Months Ended March 31,

financial information for the Company’s reportable business segments is provided for the indicated periods and as of June 30, 2022,

and June 30, 2021:

Three months ended

Six months ended

Net Revenues:

9 unchanged sentences

$ (1,130,749 )

$ (2,846,004 )

Revenue Cycle Management

2 unchanged sentences

$ (2,616,884 )

$ (13,464,590 )

$ (5,482,578 )

Depreciation and Amortization:

13 unchanged sentences

Results of Operations

experienced operating losses for the first quarter of 2022 and all quarters during 2021.

experienced operating losses for the first half of 2022 and all quarters during 2021.

The following is a summary of our recent operating

7 unchanged sentences

Operating income (loss) %

Net income (loss)

Net income (loss) attributable to common stockholders

$ (1,065,513 )

$ (6,698,242 )

$ (5,382,487 )

business is subject to substantial fluctuations on a quarterly basis as reflected in the significant variations in revenues and operating

12 unchanged sentences

and (8) the completion of corporate acquisitions.

We reported a net loss of $6,698,242

on revenues of $10,294,781 for first quarter 2022.

We reported a net loss of $1,065,513 on

revenues of $9,351,457 for the second quarter 2022.

Sheet Arrangements

6 unchanged sentences

that represent commitments to future payments for goods and services.

the Three Months Ended March 31, 2022 and 2021

the Three Months Ended June 30, 2022 and 2021

of Operations

immediately below and discussed in more detail in the subsequent subsections is an analysis of our operating results for the three months

ended March 31, 2022 and 2021, represented as a percentage of total revenues for each such quarter:

ended June 30, 2022 and 2021, represented as a percentage of total revenues for each such quarter:

Three Months Ended

13 unchanged sentences

Net income/(loss)

Net loss attributable to noncontrolling interests of consolidated

Net loss attributable to noncontrolling interests of consolidated subsidiary

Net income (loss) attributable to common stockholders

2 unchanged sentences

operating segments generate two types of revenues:

revenues primarily includes video operating segment hardware sales of in-car and body-worn cameras, along with sales of our ThermoVu TM

revenues primarily include video operating segment hardware sales of in-car and body-worn cameras, along with sales of our ThermoVu TM

units, disinfectants, and personal protective equipment.

32 unchanged sentences

Service sales

through TicketSmarter are driven largely in part by the usage of the TicketSmarter.com marketplace by buyers and sellers,

in which the Company collects service fees for each transaction completed through this platform.

through TicketSmarter are driven largely in part by the usage of the TicketSmarter.com marketplace by buyers and sellers, in which

the Company collects service fees for each transaction completed through this platform.

may discount our prices on specific orders based upon the size of the order, the specific customer and the competitive landscape.

Omicron Variant of COVID-19 had an impact on all of our operating segment revenue streams for the three months ended March 31,

In particular, it had a negative impact generally on our video solutions operating segment legacy products and, specifically, our

commercial event recorder hardware (DVM-250 Plus) and in-car hardware for law enforcement (DVM-800) during the quarter.

operating segment revenues also continues to be negatively impacted due to the cancellation of live events and public caution surrounding

the COVID-19 pandemic.

Our revenue cycle management operating segment was also affected due to the higher level of healthcare service

utilization due to the Omicron Variant while certain elective and routine healthcare services were reduced due to COVID-19 pandemic

restrictions.

revenues for the three months ended March 31, 2022 and 2021 were $2,410,060 and $1,912,577 respectively, an increase of $497,483 (26%),

Omicron variant of COVID-19 and nationwide inflationary concerns had an impact on all of our operating segment revenue streams for the

three months ended June 30, 2022.

In particular, it had a negative impact generally on our video solutions operating segment legacy products

and, specifically, our commercial event recorder hardware (DVM-250 Plus) and in-car hardware for law enforcement (DVM-800) during the

Ticketing operating segment revenues also continue to be negatively impacted due to the continued public caution surrounding

the COVID-19 pandemic and the impacts of inflation on consumer’s discretionary spending.

Product revenues by operating

segment is as follows:

Three Months Ended June 30,

Product Revenues:

Video Solutions

Revenue Cycle Management

Total Product Revenues

revenues for the three months ended June 30, 2022 and 2021 were $2,210,181 and $1,719,332 respectively, an increase of $490,849 (29%),

due to the following factors:

generated by the new ticketing operating segment began with the Company’s September 2021 acquisition of TicketSmarter.

The new ticketing operating segment generated $1,073,830 in product revenues for the three months ended March 31, 2022, compared

to $-0- for the three months ended March 31, 2021.

This product revenue relates to the resale of tickets purchased for live

events, including sporting events, concerts, and theatre, then sold through various platforms to customers.

Company’s video segment operating segment generated revenues totaling $1,336,230 during the three months ended March 31, 2022

compared to $1,912,577 for the three months ended March 31, 2021 due to slowing sales of our ThermoVu TM product

lines related to our COVID-19 response.

The Company launched two product lines in direct response to the increased safety precautions

that organizations and individuals are taking due to the COVID-19 pandemic.

ThermoVu™ was launched as a non-contact temperature-screening

instrument that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined

new ticketing operating segment generated $805,939 in product revenues for the three months ended June 30, 2022, compared to $-0-

for the three months ended June 30, 2021.

This product revenue relates to the resale of tickets purchased for live events, including

sporting events, concerts, and theatre, then sold through various platforms to customers.

Company’s video segment operating segment generated revenues totaling $1,404,242 during the three months ended June 30, 2022

compared to $1,719,332 for the three months ended June 30, 2021 due to slowing sales of our ThermoVu TM product lines related

to our COVID-19 response.

The Company launched two product lines in direct response to the increased safety precautions that organizations

and individuals are taking due to the COVID-19 pandemic.

ThermoVu™ was launched as a non-contact temperature-screening instrument

that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined

ThermoVu™ has optional features such as facial recognition to improve facility security by restricting access based

2 unchanged sentences

display and controls access to facilities based on such results.

ThermoVu TM has been applied in schools, dental office,

ThermoVu TM has been applied in schools, dental offices,

hospitals, office buildings, and other public venues.

3 unchanged sentences

The Shield™ Cleanser product line contains a cleanser with no harsh chemicals or fumes.

Company is beginning to experience pressure on these product lines as the COVID-19 pandemic begins to subside.

general, our video solutions operating segment has experienced pressure on its product revenues as our in-car and body-worn systems

are facing increased competition because our competitors have released new products with advanced features.

Additionally, our law

enforcement revenues declined over the prior period due to price-cutting and competitive actions by our competitors, adverse marketplace

effects related to our patent litigation proceedings and our recent financial condition.

We introduced our new body-worn cameras,

the FirstVu Pro and FirstVu II, in the fourth quarter of 2021, as we have begun to see increased traction with these products

in the first quarter of 2022.

The Company hopes the interest throughout the marketplace continues to grow for these new products

as the market is able to review and test these new products.

video solutions operating segment management has been focusing on migrating customers, and in particular commercial customers, from

a hardware sale to a service fee model.

Therefore, we expect a reduction in commercial hardware sales (principally DVM-250’s,

FLT-250’s, and our body-worn camera line) as we convert these customers to a service model under which we provide the hardware

as part of a recurring monthly service fee.

In that respect, we introduced a monthly subscription agreement plan for our body worn

cameras and related equipment during the second quarter of 2020 that allowed law enforcement agencies to pay a monthly service fee

to obtain body worn cameras without incurring a significant upfront capital outlay.

This program has continued to gain traction,

resulting in decreased product revenues and increasing our service revenues.

We expect this program to continue to hold traction,

Company is beginning to experience decreased demand for these product lines as the COVID-19 pandemic begins to subside.

our video solutions operating segment has experienced decreased demand on its product revenues due to price-cutting and competitive actions

by our competitors, adverse marketplace effects related to our patent litigation proceedings and our recent financial condition.

We introduced

our new body-worn cameras, the FirstVu Pro and FirstVu II, in the fourth quarter of 2021, and we have begun to see increased traction

with these products in the first and second quarters of 2022.

The Company hopes the interest throughout the marketplace continues to

grow for these new products as the market is able to review and test these new products.

Our video solutions operating segment management has been focusing on migrating

customers, and in particular commercial customers, from a hardware sale to a service fee model.

Therefore, we expect a reduction in commercial

hardware sales (principally DVM-250’s, FLT-250’s, and our body-worn camera line) as we convert these customers to a service

model under which we provide the hardware as part of a recurring monthly service fee.

In that respect, we introduced a monthly subscription

agreement plan for our body worn cameras and related equipment during the second quarter of 2020 that allowed law enforcement agencies

to pay a monthly service fee to obtain body worn cameras without incurring a significant upfront capital outlay.

This program has continued

to gain traction, resulting in decreased product revenues and increased service revenues.

We expect this program to continue to gain momentum,

resulting in recurring revenues over a span of three to five years.

and other revenues for the three months ended March 31, 2022 and 2021 were $7,884,721 and $623,252, respectively, an increase of $7,261,469

Service and other revenues by

operating segment is as follows:

Three Months Ended June 30,

Service and Other Revenues:

Video Solutions

Revenue Cycle Management

Total Service and Other Revenues

and other revenues for the three months ended June 30, 2022 and 2021 were $7,141,276 and $774,339, respectively, an increase of $6,366,937

(822%), due to the following factors:

revenues generated by the video solutions operating segment were $270,925 and $241,653 for the three months ended March 31, 2022

and 2021, respectively, an increase of $29,272 (12%).

revenues generated by the video solutions operating segment were $365,599 and $247,085 for the three months ended June 30, 2022 and

2021, respectively, an increase of $118,514 (48%).

We have experienced increased interest in our cloud solutions for law enforcement

primarily due to the deployment of our cloud-based EVO-HD in-car system and our next generation body-worn camera products, which

contributed to our increased cloud revenues in the three months ended March 31, 2022.

contributed to our increased cloud revenues in the three months ended June 30, 2022.

We expect this trend to continue throughout

2022 as the migration from local storage to cloud storage continues in our customer base.

solutions operating segment revenues from extended warranty services were $199,491 and $254,692 for the three months ended March

31, 2022 and 2021, respectively, a decrease of $55,201 (22%).

We have many customers that have purchased extended warranty packages,

primarily in our DVM-800 premium service program.

However, the continued affects from the COVID-19 pandemic has adversely

affected our sales of DVM-800 hardware systems resulting in a decrease in their sales in the three months ended March 31, 2022 compared

to the same period in 2021.

new ticketing operating segment generated service revenues totaling $5,306,945 and $-0- for the three months ended March 31, 2022

Video solutions operating segment revenues from extended warranty services

were $163,639 and $232,614 for the three months ended June 30, 2022 and 2021, respectively, a decrease of $68,975 (30%).

continued effects from the COVID-19 pandemic have adversely affected our sales of DVM-800 hardware systems resulting in a decrease in

their sales in the three months ended June 30, 2022 compared to the same period in 2021.

new ticketing operating segment generated service revenues totaling $4,375,024 and $-0- for the three months ended June 30, 2022

and 2021, respectively, an increase of $4,375,024 (100%).

6 unchanged sentences

new revenue cycle management operating segment generated service revenues totaling $2,120,739 and $-0- for the three months ended

March 31, 2022 and 2021, respectively, an increase of $1,903,957 (100%).

June 30, 2022 and 2021, respectively, an increase of $2,120,739 (100%).

Our revenue cycle management operating segment has completed

four acquisitions since formation in June of 2021, thus resulting in the new service revenue stream added in the three months ended

March 31, 2022.

June 30, 2022.

Our revenue cycle management operating segment provides revenue cycle management solutions and back-office services

to healthcare organizations throughout the country.

We expect our revenue cycle management segment to continue to present

a strong revenue outlook moving forward.

revenues for the three months ended March 31, 2022 and 2021 were $10,294,781 and $2,535,829, respectively, an increase of $7,758,952

We expect our revenue cycle management segment to continue to present a strong

revenue outlook moving forward.

revenues for the three months ended June 30, 2022 and 2021 were $9,351,458 and $2,493,671, respectively, an increase of $6,857,786 (275%),

due to the reasons noted above.

of Product Revenue

cost of product revenue sold for the three months ended March 31, 2022, and 2021 was $2,822,051 and $1,561,310, respectively, an increase

of $1,260,741 (81%).

Overall cost of goods sold for products as a percentage of product revenues for the three months ended March 31,

2022, and 2021 were 117.1% and 81.6%, respectively.

Cost of products sold by operating segment is as follows:

Three Months Ended March 31,

cost of product revenue sold for the three months ended June 30, 2022,

and 2021 was $2,070,476 and $1,017,659, respectively, an increase of $1,052,817 (103%).

Overall cost of goods sold for products as a percentage

of product revenues for the three months ended June 30, 2022, and 2021 were 93.7% and 59.2%, respectively.

Cost of products sold by operating

segment is as follows:

Three Months Ended June 30,

Cost of Product Revenues:

2 unchanged sentences

Total Cost of Product Revenues

decrease in cost of goods sold for our video solutions segment products is directly correlated with the decrease in product sales

for the three months ended March 31, 2022 compared to the three months ended March 31, 2021.

In addition, the Video Solutions Segment

recorded valuation allowances for its older product lines and a portion of its Shield products during the first quarter of 2022.

Cost of product sold as a percentage of product revenues for the video solutions segment increased to 110.6% for the three months ended

March 31, 2022 as compared to 81.6% for the three months ended March 31, 2021.

increase in ticketing operating segment cost of product sold is due to the acquisition of TicketSmarter in the third quarter of 2021,

resulting in an increase to cost of product revenue of $1,344,336 for the three months ended March 31, 2022, compared to $-0- for

the three months ended March 31, 2021.

Cost of product sold as a percentage of product revenues for the ticketing solutions was 125.2%

for the three months ended March 31, 2022.

The Ticketing Segment recorded an allowance for unsold and under-market tickets during

the first quarter 2022 due to event cancellations and restrictions imposed on the size and type of gatherings related to the Omicron

In addition, we provide a reserve related to Major League Baseball reducing their spring training schedule and delaying their

regular season due to the player strike in the first quarter of 2022.

We recorded $3,896,460 and $3,915,089

in reserves for obsolete and excess inventories at March 31, 2022 and December 31, 2021, respectively.

Total raw materials and component

parts were $3,839,796 and $3,062,046 at March 31, 2022 and December 31, 2021, respectively, an increase of $777,750 (25%).

Finished goods

balances were $9,462,527 and $10,512,577 at March 31, 2022 and December 31, 2021, respectively, a decrease of $1,050,050 (10%) which

was attributable to a decrease in finished goods from our newly acquired ticketing segment.

The small decrease in the inventory

reserve is primarily due to the reduction in finished goods and movement of excess inventory.

We believe the reserves are appropriate

given our inventory levels as of March 31, 2022.

The decrease in cost of goods

sold for our video solutions segment products is directly correlated with the decrease in product sales for the three months ended June

30, 2022 compared to the three months ended June 30, 2021.

In addition, the video solutions segment recorded valuation allowances for

its older product lines and a portion of its Shield products during the second quarter of 2022, directly increasing cost of goods sold

for the period.

Cost of product sold as a percentage of product revenues for the video solutions segment increased to 73.3% for the three

months ended June 30, 2022 as compared to 59.2% for the three months ended June 30, 2021.

The increase in ticketing operating

segment cost of product sold is due to the acquisition of TicketSmarter in the third quarter of 2021, resulting in an increase to cost

of product revenue of $1,041,073 for the three months ended June 30, 2022, compared to $-0- for the three months ended June 30, 2021.

Cost of product sold as a percentage of product revenues for the ticketing solutions was 129.2% for the three months ended June 30, 2022.

The Ticketing Segment recorded an allowance for unsold and under-market tickets during the first quarter of 2022 due to event cancellations

and restrictions imposed on the size and type of gatherings related to the Omicron variant.

recorded $3,722,467 and $3,915,089 in reserves for obsolete and excess inventories at June 30, 2022 and December 31, 2021, respectively.

Total raw materials and component parts were $4,083,713 and $3,062,046 at June 30, 2022 and December 31, 2021, respectively, an increase

of $1,021,667 (33%).

Finished goods balances were $9,044,555 and $10,512,577 at June 30, 2022 and December 31, 2021, respectively, a

decrease of $1,468,022 (14%) which was attributable to a decrease in finished goods from our newly acquired ticketing segment.

decrease in the inventory reserve is primarily due to the reduction in finished goods and movement of excess inventory.

We believe the

reserves are appropriate given our inventory levels as of June 30, 2022.

of Service Revenue

cost of service revenue sold for the three months ended March 31, 2022, and 2021 was $5,553,111 and $162,637, respectively, an increase

cost of service revenue sold for the three months ended June 30, 2022, and 2021 was $5,561,903 and $215,212, respectively, an increase

of $5,346,691 (2,484%).

Overall cost of goods sold for services as a percentage of service revenues for the three months ended March

Overall cost of goods sold for services as a percentage of service revenues for the three months ended June 30,

2022, and 2021 were 77.9% and 27.8%, respectively.

Cost of service revenues by operating shipment is as follows:

Three Months Ended March

Cost of service revenues by operating segment is as follows:

Three Months Ended June 30,

Cost of Service Revenues:

3 unchanged sentences

increase in cost of service revenues for our video solutions segment is commensurate with the increase in service revenues in the three

months ended March 31, 2022 compared to the three months ended March 31, 2021.

months ended June 30, 2022 compared to the three months ended June 30, 2021.

Cost of service revenues as a percentage of service revenues

for the video solutions segment increased to 39.2% for the three months ended March 31, 2022 as compared to 26.1% for the three months

ended March 31, 2021.

increase in revenue cycle management operating segment cost of service revenue is due to the four acquisitions of medical billing

companies completed since June 2021.

Cost of service revenues as a percentage of product revenues for the revenue cycle

management operating segment was 36.7% for the first three months of 2022.

increase in ticketing operating segment cost of service revenues is the due to the 2021 acquisition of TicketSmarter, resulting in an

increase to cost of service revenue of $4,062,421 for the three months ended March 31, 2022, compared to $-0- for the three months ended

March 31, 2021.

Cost of service revenues as a percentage of service revenues for the ticketing was 76.5% for the three months ended March

gross profit for the three months ended March 31, 2022 and 2021 was $1,939,619 and $811,882, respectively, an increase of $1,127,737

for the video solutions segment increased to 40.5% for the three months ended June 30, 2022 as compared to 27.8% for the three months

ended June 30, 2021.

increase in revenue cycle management operating segment cost of service revenue is due to the four acquisitions of medical billing companies

completed since June 2021.

Cost of service revenues as a percentage of service revenues for the revenue cycle management operating segment

was 54.9% for the three months ended June 30, 2022.

increase in ticketing operating segment cost of service revenues is due to the 2021 acquisition of TicketSmarter, resulting in an

increase to cost of service revenue of $4,137,084 for the three months ended June 30, 2022, compared to $-0- for the three months

ended June 30, 2021.

Cost of service revenues as a percentage of service revenues for the ticketing segment was 94.6% for the three

months ended June 30, 2022.

gross profit for the three months ended June 30, 2022 and 2021 was $1,719,078

and $1,260,800, respectively, an increase of $458,278 (36.3%).

Gross profit by operating segment was as follows:

Months Ended June 30,

Gross Profit:

2 unchanged sentences

Total Gross Profit

overall increase is attributable to the large overall increase in revenues for the three months ended March 31, 2022 and an increase

in the overall cost of sales as a percentage of overall revenues to 81.1% for the three months ended March 31, 2022 from 68.0% for the

three months ended March 31, 2021.

Our goal is to improve our margins over the longer term based on the expected margins generated by

our new recent revenue cycle management and ticketing operating segments together with our video solutions operating segment and its

expected margins from our EVO-HD, DVM-800, VuLink, FirstVu Pro, FirstVu II, FirstVu HD, ThermoVu TM , Shield TM disinfectants

overall increase is attributable to the large overall increase in revenues for the three months ended June 30, 2022 and an increase in

the overall cost of sales as a percentage of overall revenues to 81.6% for the three months ended June 30, 2022 from 49.4% for the three

months ended June 30, 2021.

Our goal is to improve our margins over the longer term based on the expected margins generated by our new

recent revenue cycle management and ticketing operating segments together with our video solutions operating segment and its expected

margins from our EVO-HD, DVM-800, VuLink, FirstVu Pro, FirstVu II, FirstVu HD, ThermoVu TM , Shield TM disinfectants

and our cloud evidence storage and management offering, provided that they gain traction in the marketplace and subject to a normalizing

economy in the wake of the COVID-19 pandemic.

In addition, if revenues from the video solutions segment increase, we will seek to further

improve our margins from this segment through expansion and increased efficiency utilizing fixed manufacturing overhead components.

plan to continue our initiative to more efficient management of our supply chain through outsourcing production, quantity purchases and

more effective purchasing practices.

economy in the wake of the COVID-19 pandemic and current inflationary concerns.

In addition, if revenues from the video solutions segment

increase, we will seek to further improve our margins from this segment through expansion and increased efficiency utilizing fixed manufacturing

overhead components.

We plan to continue our initiative to more efficient management of our supply chain through outsourcing production,

quantity purchases and more effective purchasing practices.

General and Administrative Expenses

general and administrative expenses were $8,742,957 and $3,677,575 for the three months ended March 31, 2022 and 2021, respectively,

an increase of $5,065,382 (137.7%).

The increase was primarily attributable to the recent acquisitions completed in the third quarter

Our selling, general and administrative expenses as a percentage of sales decreased to 85% for the three months ended March

31, 2022 compared to 145% in the same period in 2021.

The significant components of selling, general and administrative expenses are

general and administrative expenses were $8,380,330 and $3,877,684 for

the three months ended June 30, 2022 and 2021, respectively, an increase of $4,502,646 (116.1%).

The increase was primarily attributable

to the recent acquisitions completed in the third quarter of 2021.

Our selling, general and administrative expenses as a percentage of

sales decreased to 90% for the three months ended June 30, 2022 compared to 156% in the same period in 2021.

The significant components

of selling, general and administrative expenses are as follows:

Three months ended

4 unchanged sentences

We continue to focus on bringing new products to market, including updates and improvements to current

Our research and development expenses totaled $498,000 and $448,965 for the three months ended March 31, 2022 and 2021, respectively,

Our research and development expenses totaled $540,222 and $460,999 for the three months ended June 30, 2022 and 2021, respectively,

an increase of $79,223 (17.2%).

6 unchanged sentences

on a prudent basis and consistent with our financial resources.

advertising and promotional expenses.

Selling, advertising and promotional expense totaled $2,779,404 and $596,755 for the three

months ended March 31, 2022 and 2021, respectively, an increase of $2,182,649 (365.8%).

Promotional and advertising expenses represent

the primary component of these costs and totaled $2,389,063 during the three months ended March 31, 2022, compared to $197,203 during

the three months ended March 31, 2021, an increase of $2,191,860 (1,111.5%).

The increase is primarily attributable to the 2022 sponsorship

of NASCAR and IndyCar.

Additionally, TicketSmarter is very active in sponsorship and advertising, as it continues to build its

brand and gain recognition.

TicketSmarter accounted for $1,458,267 of the total promotional and advertising expense for the three

months ended March 31, 2022.

and administrative expense .

General and administrative expenses totaled $5,465,553 and $2,631,855 for the three months ended

March 31, 2022 and 2021, respectively, an increase of $2,833,698 (107.7%).

The increase in general and administrative expenses in the

three months ended March 31, 2022 compared to the same period in 2021 is primarily attributable to an increase in administrative salaries,

as payroll continues to increase with the new acquisition completed by the Company.

General and administrative expense also increased

due to a substantial increase in depreciation and amortization, rent expenses, and legal and professional expenses for the three

months ended March 31, 2022 compared to the same period in 2021.

the reasons stated above, our operating loss was $6,803,338 and $2,865,693 for the three months ended March 31, 2022 and 2021, respectively,

an increase of $3,937,645 (137.4%).

Operating loss as a percentage of revenues improved to 66% in the three months ended March 31, 2022

from 113% in the same period in 2021.

income increased to $71,362 for the three months ended March 31, 2022, from $41,686 in the same period of 2021, which reflects our improved

cash and cash equivalent levels in the first quarter of 2022 compared to the first quarter of 2021.

Selling, advertising and

promotional expenses.

Selling, advertising and promotional expense totaled $2,763,045 and $870,183 for the three months ended

June 30, 2022 and 2021, respectively, an increase of $1,892,862 (217.5%).

Promotional and advertising expenses represent the primary component

of these costs and totaled $2,361,235 during the three months ended June 30, 2022, compared to $373,968 during the three months ended

June 30, 2021, an increase of $1,987,267 (531.4%).

The increase is primarily attributable to the 2022 sponsorship of NASCAR and IndyCar.

Additionally, TicketSmarter remains active in sponsorship and advertising.

TicketSmarter accounted for $1,394,622 of the total promotional

and advertising expense for the three months ended June 30, 2022.

General and administrative

General and administrative expenses totaled $5,077,063 and $2,546,502 for the three months ended June 30, 2022 and 2021,

respectively, an increase of $2,530,561 (99.4%).

The increase in general and administrative expenses in the three months ended June 30,

2022 compared to the same period in 2021 is primarily attributable to an increase in administrative salaries, as payroll continues to

increase with the new acquisition completed by the Company’s healthcare venture during the first half of 2022.

General and administrative

expense also increased due to a substantial increase in depreciation and amortization, rent expenses, and legal and professional expenses

for the three months ended June 30, 2022 compared to the same period in 2021, as a result of the numerous acquisitions completed by the

Company that were not relevant to the same period in 2021.

the reasons stated above, our operating loss was $6,661,252 and $2,616,884

for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,044,368 (154.5%).

Operating loss as a percentage

of revenues improved to 71% in the three months ended June 30, 2022 from 105% in the same period in 2021.

income increased to $32,233 for the three months ended June 30, 2022, from $90,774 in the same period of 2021, which reflects our change

cash and cash equivalent levels in the second quarter of 2022 compared to the second quarter of 2021.

The Company held significant cash

and cash equivalents throughout the first quarter of 2022, allowing a full three months of interest income.

Compared to the completed

two registered direct offerings in the first quarter of 2021 which yielded net proceeds of approximately $66.4 million which balances

earned interest income for the latter part of the first quarter of 2021.

incurred interest expense of $17,009 and $1,428 during the three months ended March 31, 2022 and 2021, respectively.

increase is attributable to the contingent earn-out notes associated with the four Nobility Healthcare acquisitions, currently at a total

balance of $1,762,064 for the four notes, with interest rates of 3.00% per annum.

and cash equivalents throughout the second quarter of 2021, allowing a full three months of interest income due to the two completed

registered direct offerings in the first quarter of 2021 which yielded net proceeds of approximately $66.4 million.

incurred interest expense of $8,501 and $1,365 during the three months

ended June 30, 2022 and 2021, respectively.

The increase is attributable to the contingent earn-out notes associated with the four Nobility

Healthcare acquisitions, currently at a total balance of $1,119,344 for the four notes, with interest rates of 3.00% per annum.

in Fair Value of Short-Term Investments

recognized a loss on change in fair value of short-term investments totaling $84,818 and $4,964 during the three months

ended March 31, 2022 and 2021, respectively.

Such short-term investments are included in cash and cash equivalents as they contain original

maturities of ninety (90) days or less.

The Company completed two registered direct offerings in the first quarter of 2021, which

yielded net proceeds of approximately $66.4 million, a portion of which was invested in short-term securities with original maturities

of 90 days or less.

recognized a loss on change in fair value of short-term investments totaling $-0- and $1,590 during the three months ended June 30, 2022

and 2021, respectively.

Such short-term investments are included in cash and cash equivalents as they contain original maturities of

ninety (90) days or less.

in Fair Value of Contingent Consideration Promissory Notes

During 2021, the Company issued

a contingent consideration promissory note in connection with the two acquisitions made by our revenue cycle management segment

in the amount of $350,000 and $650,000.

Management’s estimate of the fair value of the $350,000 contingent promissory note

at March 31, 2022 decreased by $51,464 compared to its estimated fair value at December 31, 2021.

Management’s estimate

of the fair value of the $650,000 contingent promissory note at March 31, 2022 increased by $107,514 compared to its estimated

fair value at December 31, 2021.

Therefore, the Company recorded a net loss of $56,050 in the Consolidated Statements

of Operations for the three months ended March 31, 2022.

the three months ended June 30, 2022, The Company recognized a gain on

the change in fair value of contingent consideration promissory notes of $542,096 and $-0- during the three months ended June 30, 2022

and 2021, respectively.

This is in connection with the four acquisitions made by our revenue cycle management segment.

in Fair Value of Derivative Liabilities

During the first quarter of 2021,

the Company issued detachable warrants to purchase a total of 42,500,000 shares of Common Stock in association with the two registered

direct offerings previously described.

The underlying warrant agreement terms provide for net cash settlement outside the control of the

Company in the event of tender offers under certain circumstances.

As such, the Company is required to treat these warrants as derivative

liabilities which are valued at their estimated fair value at their issuance date and at each reporting date with any subsequent changes

reported in the condensed consolidated statement of operations as the change in fair value of warrant derivative liabilities.

in fair value of the warrant derivative liabilities from December 31, 2021, to March 31, 2022, totaled $148,171 which was recognized as

a gain in the first quarter of 2022.

The Company determined the fair value of such warrants as of December 31, 2021, and as of March 31,

2022, to be $14,846,932 and $14,698,761, respectively.

Income/(Loss)

the first quarter of 2021, the Company issued detachable warrants to purchase a total of 42,500,000 shares of Common Stock in association

with the two registered direct offerings previously described.

The underlying warrant agreement terms provide for net cash settlement

outside the control of the Company in the event of tender offers under certain circumstances.

As such, the Company is required to treat

these warrants as derivative liabilities which are valued at their estimated fair value at their issuance date and at each reporting

date with any subsequent changes reported in the condensed consolidated statement of operations as the change in fair value of warrant

derivative liabilities.

The change in fair value of the warrant derivative liabilities from March 31, 2022, to June 30, 2022, totaled

$5,413,618 which was recognized as a gain in the second quarter of 2022.

The Company determined the fair value of such warrants as of

March 31, 2022, and as of June 30, 2022, to be $14,698,761 and $9,285,143, respectively.

before Income Tax Benefit

a result of the above results of operations, we reported an income/(loss) before income tax benefit of ($6,698,242) and $21,721,858 for

the three months ended March 31, 2022 and 2021, respectively, a decrease of $28,420,100 (130.8%).

did not record an income tax expense related to our income for the three months ended March 31, 2022 due to our overall net operating

a result of the above results of operations, we reported a loss before

income tax benefit of $682,187 and $5,382,487 for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,700,300

did not record an income tax expense related to our income for the three months ended June 30, 2022 due to our overall net operating

loss carryforwards available.

We have further determined to continue providing a full valuation reserve on our net deferred tax assets

as of March 31, 2022.

We had approximately $81.4 million of net operating loss carryforwards and $1,8 million of research

and development tax credit carryforwards as of March 31, 2022 available to offset future net taxable income.

Income/(Loss)

a result of the above results of operations, we reported net income/(loss) of ($6,698,242) and $21,721,858 for the three months ended

March 31, 2022 and 2021, respectively, a decrease of $28,420,100 (130.8%).

Loss Attributable to Noncontrolling Interests of Consolidated Subsidiary

Company owns a 51% equity interest in its consolidated subsidiary, Nobility Healthcare.

As a result, the noncontrolling shareholders

or minority interest is allocated 49% of the income/loss of Nobility Healthcare which is reflected in the statement of income (loss)

as “net income (loss) attributable to noncontrolling interests of consolidated subsidiary”.

We reported net loss attributable to noncontrolling interests of consolidated subsidiary of $98,094 and $-0- for the three months ended March 31, 2022 and

as of June 30, 2022.

We had approximately $81.4 million of net operating loss carryforwards and $1.8 million of research and development

tax credit carryforwards as of June 30, 2022 available to offset future net taxable income.

a result of the above results of operations, we reported a net loss of $682,187

and $5,382,487 for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,700,300 (87.3%).

Income Attributable to Noncontrolling Interests of Consolidated Subsidiary

Company owns a 51% equity interest in its consolidated subsidiary, Nobility

As a result, the noncontrolling shareholders or minority interest is allocated 49% of the income of Nobility Healthcare which

is reflected in the statement of income as “net income attributable to noncontrolling interests of consolidated subsidiary”.

We reported net income attributable to noncontrolling interests of consolidated subsidiary of $383,326 and $-0- for the three months ended

June 30, 2022 and 2021, respectively.

Loss Attributable to Common Stockholders

a result of the above, we reported a net loss attributable to common stockholders

of $1,065,513 and $5,382,487 for the years three months June 30, 2022 and 2021, respectively, an increase of $4,316,974 (80.2%).

and Diluted Loss per Share

basic and diluted loss per share was $0.02 and $0.10 for the three months ended June 30, 2022 and 2021, respectively.

Basic loss per

share is based upon the weighted average number of common shares outstanding during the period.

For the three months ended June 30, 2022

and 2021, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options and warrants were antidilutive,

and, therefore, not included in the computation of diluted loss per share.

the Six Months Ended June 30, 2022 and 2021

of Operations

immediately below and discussed in more detail in the subsequent subsections is an analysis of our operating results for the six months

ended June 30, 2022 and 2021, represented as a percentage of total revenues for each such quarter:

Six Months Ended

Cost of revenue

Selling, general and administrative expenses:

Research and development expense

Selling, advertising and promotional expense

General and administrative expense

Total selling, general and administrative expenses

Operating loss

Change in fair value of contingent consideration promissory notes

Change in fair value of derivative liabilities

Other income and interest income (expense), net

Income (loss) before income tax benefit

Income tax (provision)

Net income/(loss)

Net loss attributable to noncontrolling interests of consolidated subsidiary

Net income (loss) attributable to common stockholders

Net income/(loss) per share information:

Product revenues by operating

segment is as follows:

Six Months Ended June 30,

Product Revenues:

Video Solutions

Revenue Cycle Management

Total Product Revenues

revenues for the six months ended June 30, 2022 and 2021 were $4,620,241 and $3,631,910 respectively, an increase of $988,331 (27%),

due to the following factors:

generated by the new ticketing operating segment began with the Company’s September 2021 acquisition of TicketSmarter.

new ticketing operating segment generated $1,879,769 in product revenues for the six months ended June 30, 2022, compared to $-0-

for the six months ended June 30, 2021.

This product revenue relates to the resale of tickets purchased for live events, including

sporting events, concerts, and theatre, then sold through various platforms to customers.

Company’s video segment operating segment generated revenues totaling $2,740,472 during the six months ended June 30, 2022

compared to $3,631,910 for the six months ended June 30, 2021 due to slowing sales of our ThermoVu TM product lines related

to our COVID-19 response.

The Company launched two product lines in direct response to the increased safety precautions that organizations

and individuals are taking due to the COVID-19 pandemic.

ThermoVu™ was launched as a non-contact temperature-screening instrument

that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined

ThermoVu™ has optional features such as facial recognition to improve facility security by restricting access based

on temperature and/or facial recognition reasons.

ThermoVu™ provides an instant pass/fail audible tone with its temperature

display and controls access to facilities based on such results.

ThermoVu TM has been applied in schools, dental office,

hospitals, office buildings, and other public venues.

The Company also launched its Shield™ disinfectant/sanitizer product

lines to fulfill demand by current customers and others for a disinfectant and sanitizer that is less harsh than many of the traditional

products now widely distributed.

The Shield™ Cleanser product line contains a cleanser with no harsh chemicals or fumes.

Company is beginning to experience decreased demand on these product lines as the COVID-19 pandemic begins to subside.

general, our video solutions operating segment has experienced decreased demand on its product revenues due to price-cutting and competitive

actions by our competitors, adverse marketplace effects related to our patent litigation proceedings and our recent financial condition.

We introduced our new body-worn cameras, the FirstVu Pro and FirstVu II, in the fourth quarter of 2021, and we have begun to see increased

traction with these products in the first six months of 2022.

The Company hopes the interest throughout the marketplace continues

to grow for these new products as the market is able to review and test these new products.

Our video solutions operating segment management has been focusing on migrating

customers, and in particular commercial customers, from a hardware sale to a service fee model.

Therefore, we expect a reduction in commercial

hardware sales (principally DVM-250’s, FLT-250’s, and our body-worn camera line) as we convert these customers to a service

model under which we provide the hardware as part of a recurring monthly service fee.

In that respect, we introduced a monthly subscription

agreement plan for our body worn cameras and related equipment during the second quarter of 2020 that allowed law enforcement agencies

to pay a monthly service fee to obtain body worn cameras without incurring a significant upfront capital outlay.

This program has continued

to gain traction, resulting in decreased product revenues and increased service revenues.

We expect this program to continue to gain momentum,

resulting in recurring revenues over a span of three to five years.

Service and other revenues by

operating segment is as follows:

Six Months Ended June 30,

Service and Other Revenues:

Video Solutions

Revenue Cycle Management

Total Service and Other Revenues

and other revenues for the six months ended June 30, 2022 and 2021 were $15,025,997 and $1,397,591, respectively, an increase of $13,628,406

(975%), due to the following factors:

revenues generated by the video solutions operating segment were $627,874 and $488,738 for the six months ended June 30, 2022 and

2021, respectively, an increase of $139,136 (28.5%).

We have experienced increased interest in our cloud solutions for law enforcement

primarily due to the deployment of our cloud-based EVO-HD in-car system and our next generation body-worn camera products, which

contributed to our increased cloud revenues in the six months ended June 30, 2022.

We expect this trend to continue throughout 2022

as the migration from local storage to cloud storage continues in our customer base.

Video solutions operating segment revenues from extended warranty services

were $363,130 and $487,307 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $124,177 (25.5%).

continued effects from the COVID-19 pandemic have adversely affected our sales of DVM-800 hardware systems resulting in a decrease in

their sales in the six months ended June 30, 2022 compared to the same period in 2021.

new ticketing operating segment generated service revenues totaling $9,681,969 and $-0- for the six months ended June 30, 2022 and

2021, respectively, an increase of $9,681,969 (100%).

The Company completed the acquisitions of Goody Tickets, LLC and TicketSmarter,

LLC on September 1, 2021, thus resulting in the new revenue stream for the Company.

TicketSmarter collects fees on transactions administered

through the TicketSmarter.com platform for the buying and selling of tickets for live events throughout the country.

We expect our

ticketing operating segment to continue to present a strong revenue outlook moving forward.

new revenue cycle management operating segment generated service revenues totaling $4,024,695 and $-0- for the six months ended June

30, 2022 and 2021, respectively, an increase of $4,024,695 (100%).

Our revenue cycle management operating segment has completed four

acquisitions since formation in June of 2021, thus resulting in the new service revenue stream added in the six months ended June

Our revenue cycle management operating segment provides revenue cycle management solutions and back-office services to

healthcare organizations throughout the country.

We expect our revenue cycle management segment to continue to present a strong revenue

outlook moving forward.

revenues for the six months ended June 30, 2022 and 2021 were $19,646,238 and $5,029,501, respectively, an increase of $14,616,737 (291%),

due to the reasons noted above.

of Product Revenue

Overall cost of product revenue

sold for the six months ended June 30, 2022, and 2021 was $4,892,527 and $2,578,969, respectively, an increase of $2,313,558 (89.7%).

Overall cost of goods sold for products as a percentage of product revenues for the six months ended June 30, 2022, and 2021 were 105.8%

and 71.0%, respectively.

Cost of products sold by operating segment is as follows:

Six Months Ended June 30,

Cost of Product Revenues:

Video Solutions

Revenue Cycle Management

Total Cost of Product Revenues

The decrease in cost of goods

sold for our video solutions segment products is directly correlated with the decrease in product sales for the six months ended June

30, 2022 compared to the six months ended June 30, 2021.

In addition, the video solutions segment recorded valuation allowances for its

older product lines and a portion of its Shield products during the first six months of 2022, directly increasing cost of goods sold for

Cost of product sold as a percentage of product revenues for the video solutions segment increased to 91.5% for the six months

ended June 30, 2022 as compared to 71.0% for the six months ended June 30, 2021.

increase in ticketing operating segment cost of product sold is due to the acquisition of TicketSmarter in the third quarter of 2021,

resulting in an increase to cost of product revenue of $2,385,409 for the six months ended June 30, 2022, compared to $-0- for the six

months ended June 30, 2021.

Cost of product sold as a percentage of product revenues for the ticketing solutions was 126.9% for the six

months ended June 30, 2022.

The Ticketing Segment recorded an allowance for unsold and under-market tickets during the first quarter

2022 due to event cancellations and restrictions imposed on the size and type of gatherings related to the Omicron variant.

recorded $3,722,467 and $3,915,089 in reserves for obsolete and excess inventories at June 30, 2022 and December 31, 2021, respectively.

Total raw materials and component parts were $4,083,713 and $3,062,046 at June 30, 2022 and December 31, 2021, respectively, an increase

of $1,021,667 (33%).

Finished goods balances were $9,044,555 and $10,512,577 at June 30, 2022 and December 31, 2021, respectively, a

decrease of $1,468,022 (14%) which was attributable to a decrease in finished goods from our newly acquired ticketing segment.

decrease in the inventory reserve is primarily due to the reduction in finished goods and movement of excess inventory.

We believe the

reserves are appropriate given our inventory levels as of June 30, 2022.

of Service Revenue

cost of service revenue sold for the six months ended June 30, 2022, and 2021 was $11,095,015 and $377,849, respectively, an increase

of $10,717,166 (2,836%).

Overall cost of goods sold for services as a percentage of service revenues for the six months ended June 30,

2022, and 2021 were 73.8% and 27.0%, respectively.

Cost of service revenues by operating segment is as follows:

Six Months Ended June 30,

Cost of Service Revenues:

Video Solutions

Revenue Cycle Management

Total Cost of Service Revenues

increase in cost of service revenues for our video solutions segment is commensurate with the increase in service revenues in the six

months ended June 30, 2022 compared to the six months ended June 30, 2021.

Cost of service revenues as a percentage of service revenues

for the video solutions segment increased to 39.8% for the six months ended June 30, 2022 as compared to 27.0% for the six months ended

June 30, 2021.

increase in revenue cycle management operating segment cost of service revenue is due to the four acquisitions of medical billing companies

completed since June 2021.

Cost of service revenues as a percentage of service revenues for the revenue cycle management operating segment

was 58.9% for the six months ended June 30, 2022.

increase in ticketing operating segment cost of service revenues is the due to the 2021 acquisition of TicketSmarter, resulting in

an increase to cost of service revenue of $8,199,505 for the six months ended June 30, 2022, compared to $-0- for the six months

ended June 30, 2021.

Cost of service revenues as a percentage of service revenues for the ticketing segment was 84.7% for the six

months ended June 30, 2022.

gross profit for the six months ended June 30, 2022 and 2021 was $3,658,696

and $2,072,683, respectively, an increase of $1,586,013 (76.5%).

Gross profit by operating segment was as follows:

Six Months Ended June 30,

Gross Profit:

Video Solutions

Revenue Cycle Management

Total Gross Profit

overall increase is attributable to the large overall increase in revenues

for the six months ended June 30, 2022 and an increase in the overall cost of sales as a percentage of overall revenues to 81.4% for the

six months ended June 30, 2022 from 58.8% for the six months ended June 30, 2021.

Our goal is to improve our margins over the longer term

based on the expected margins generated by our new recent revenue cycle management and ticketing operating segments together with our

video solutions operating segment and its expected margins from our EVO-HD, DVM-800, VuLink, FirstVu Pro, FirstVu II, FirstVu HD, ThermoVu TM ,

Shield TM disinfectants and our cloud evidence storage and management offering, provided that they gain traction in the marketplace

and subject to a normalizing economy in the wake of the COVID-19 pandemic and current inflationary concerns.

In addition, if revenues

from the video solutions segment increase, we will seek to further improve our margins from this segment through expansion and increased

efficiency utilizing fixed manufacturing overhead components.

We plan to continue our initiative to more efficient management of our supply

chain through outsourcing production, quantity purchases and more effective purchasing practices.

General and Administrative Expenses

Selling, general and administrative expenses were $17,123,286 and $7,555,261 for

the six months ended June 30, 2022 and 2021, respectively, an increase of $9,568,025 (126.6%).

The increase was primarily attributable

to the recent acquisitions completed in the third quarter of 2021.

Our selling, general and administrative expenses as a percentage of

sales decreased to 87% for the six months ended June 30, 2022 compared to 150% in the same period in 2021.

The significant components

of selling, general and administrative expenses are as follows:

Six months ended

Research and development expense

Selling, advertising and promotional expense

General and administrative expense

and development expense.

We continue to focus on bringing new products to market, including updates and improvements to current

Our research and development expenses totaled $1,038,222 and $909,964 for the six months ended June 30, 2022 and 2021, respectively,

an increase of $128,258 (14.1%).

Most of our engineers are dedicated to research and development activities for new products, primarily

the new generation of body-worn cameras, EVO-HD and non-mirror based DVM-250 that can be located in multiple places in a vehicle.

expect our research and development activities will continue to trend higher in future quarters as we continue to expand our product

offerings based on our new body-worn camera and EVO-HD product platform and as we outsource more development projects.

We consider our

research and development capabilities and new product focus to be a competitive advantage and intend to continue to invest in this area

on a prudent basis and consistent with our financial resources.

Selling, advertising and

promotional expenses.

Selling, advertising and promotional expense totaled $5,542,448 and $1,466,938 for the six months ended

June 30, 2022 and 2021, respectively, an increase of $4,075,510 (277.8%).

Promotional and advertising expenses represent the primary component

of these costs and totaled $4,750,298 during the six months ended June 30, 2022, compared to $571,171 during the six months ended June

30, 2021, an increase of $4,179,127 (731.7%).

The increase is primarily attributable to the 2022 sponsorship of NASCAR and IndyCar.

Additionally,

TicketSmarter remains in sponsorship and advertising.

TicketSmarter accounted for $2,852,888 of the total promotional and advertising

expense for the six months ended June 30, 2022.

General and administrative

General and administrative expenses totaled $10,542,616 and $5,178,359 for the six months ended June 30, 2022 and 2021,

respectively, an increase of $5,364,258 (103.6%).

The increase in general and administrative expenses in the six months ended June 30,

2022 compared to the same period in 2021 is primarily attributable to an increase in administrative salaries, as payroll continues to

increase with the new acquisition completed by the Company’s healthcare venture during the first half of 2022.

General and administrative

expense also increased due to a substantial increase in depreciation and amortization, rent expenses, and legal and professional expenses

for the six months ended June 30, 2022 compared to the same period in 2021, as a result of the numerous acquisitions completed by the

Company that were not relevant to the same period in 2021.

For the reasons stated above,

our operating loss was $13,464,590 and $5,482,578 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $7,982,012

Operating loss as a percentage of revenues improved to 69% in the six months ended June 30, 2022 from 109% in the same period

income decreased to $103,595 for the six months ended June 30, 2022, from $132,461 in the same period of 2021, which reflects our

change in cash and cash equivalent levels in the second quarter of 2022 compared to the second quarter of 2021.

The Company held

significant cash and cash equivalents throughout the second quarter of 2021, allowing a full six months of interest income due to

the two completed registered direct offerings in the first quarter of 2021 which yielded net proceeds of approximately $66.4

incurred interest expense of $25,511 and $2,793 during the six months ended

June 30, 2022 and 2021, respectively.

The increase is attributable to the contingent earn-out notes associated with the four Nobility

Healthcare acquisitions, currently at a total balance of $1,119,344 for the four notes, with interest rates of 3.00% per annum.

in Fair Value of Short-Term Investments

recognized a loss on change in fair value of short-term investments totaling $84,818 and $6,554 during the six months ended June 30,

2022 and 2021, respectively.

Such short-term investments are included in cash and cash equivalents as they contain original maturities

of ninety (90) days or less.

in Fair Value of Contingent Consideration Promissory Notes

the six months ended June 30, 2022, The Company recognized a gain on the

change in fair value of contingent consideration promissory notes of $486,046 and $-0- during the six months ended June 30, 2022 and 2021,

respectively.

This is in connection with the four acquisitions made by our revenue cycle management segment.

in Fair Value of Derivative Liabilities

the first quarter of 2021, the Company issued detachable warrants to purchase a total of 42,500,000 shares of Common Stock in association

with the two registered direct offerings previously described.

The underlying warrant agreement terms provide for net cash settlement

outside the control of the Company in the event of tender offers under certain circumstances.

As such, the Company is required to treat

these warrants as derivative liabilities which are valued at their estimated fair value at their issuance date and at each reporting

date with any subsequent changes reported in the condensed consolidated statement of operations as the change in fair value of warrant

derivative liabilities.

The change in fair value of the warrant derivative liabilities from December 31, 2021, to June 30, 2022, totaled

$5,561,789 which was recognized as a gain in the second quarter of 2022.

The Company determined the fair value of such warrants as of

December 31, 2021, and as of June 30, 2022, to be $14,846,932 and $9,285,143, respectively.

Income/(Loss)

before Income Tax Benefit

a result of the above results of operations, we reported an income/(loss)

before income tax benefit of ($7,380,430) and $16,339,371 for the six months ended June 30, 2022 and 2021, respectively, a decrease of

$23,719,802 (145.2%).

did not record an income tax expense related to our income for the six months ended June 30, 2022 due to our overall net operating loss

carryforwards available.

We have further determined to continue providing a full valuation reserve on our net deferred tax assets as

of June 30, 2022.

We had approximately $81.4 million of net operating loss carryforwards and $1.8 million of research and development

tax credit carryforwards as of June 30, 2022 available to offset future net taxable income.

Income/(Loss)

a result of the above results of operations, we reported a net income/(loss)

of $(7,380,430) and $16,339,371 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $23,719,802 (145.2%).

Income Attributable to Noncontrolling Interests of Consolidated Subsidiary

Company owns a 51% equity interest in its consolidated subsidiary, Nobility

As a result, the noncontrolling shareholders or minority interest is allocated 49% of the income of Nobility Healthcare which

is reflected in the statement of income as “net income attributable to noncontrolling interests of consolidated subsidiary”.

We reported net income attributable to noncontrolling interests of consolidated subsidiary of $285,232 and $-0- for the six months ended

June 30, 2022 and 2021, respectively.

Income/(Loss) Attributable to Common Stockholders

a result of the above, we reported a net income/(loss) attributable to common stockholders of ($6,600,148) and $21,721,858 for

the years three months March 31, 2022 and 2021, respectively, a deterioration of $28,322,006 (130.4%).

a result of the above, we reported a net income/(loss) attributable to

common stockholders of ($7,665,662) and $16,339,371 for the years six months June 30, 2022 and 2021, respectively, a decrease of $24,005,033

and Diluted Income/(Loss) per Share

basic and diluted income/(loss) per share was ($0.13) and $0.49 for the three months ended March 31, 2022 and 2021, respectively.

income (loss) per share is based upon the weighted average number of common shares outstanding during the period.

For the three months

ended March 31, 2022 and 2021, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options

and warrants were antidilutive, and, therefore, not included in the computation of diluted income (loss) per share.

basic and diluted loss per share was ($0.15) and $0.34 for the six months

ended June 30, 2022 and 2021, respectively.

Basic loss per share is based upon the weighted average number of common shares outstanding

during the period.

For the six months ended June 30, 2022 and 2021, all shares issuable upon conversion of convertible debt and the exercise

of outstanding stock options and warrants were antidilutive, and, therefore, not included in the computation of diluted loss per share.

and Capital Resources

6 unchanged sentences

net proceeds of approximately $66.4 million in registered direct offerings of common stock, pre-funded warrants and warrants during 2021.

Furthermore, the Company’s only remaining interest-bearing debt at March 31, 2022 is $150,000 remaining due on the

promissory notes under the SBA’s PPP and EIDL programs, along with the four acquired private medical billing companies’ contingent

consideration promissory notes, as more fully described in Note 3, “Debt Obligations” .

We believe that the

net proceeds from the registered direct offerings will be sufficient to fund our operations during the remainder of 2022

and management believes that it now has adequate liquidity for the foreseeable future from the recently completed registered direct offerings

Such offerings were completed through utilization of the Company’s shelf-registration statement on Form S-3 (File No.

333-239419), which was initially filed with the U.S.

Securities and Exchange Commission (the “SEC) on June 25, 2020 and was declared

effective on July 2, 2020 (the “Shelf Registration Statement”).

Registration Statement on Form S-3 - The Shelf Registration Statement allows the Company to offer and sell, from time to time in

one or more offerings, any combination of our shares of common stock, debt securities, debt securities convertible into common

stock or other securities in any combination thereof, rights to purchase shares of common stock or other securities in any

combination thereof, warrants to purchase shares of common stock or other securities in any combination thereof or units consisting

of common stock or other securities in any combination thereof having an aggregate initial offering price not exceeding $125,000,000.

Furthermore, the Company’s only remaining interest-bearing debt at June 30, 2022 is $150,000 remaining due on the promissory notes

under the SBA’s PPP and EIDL programs, along with the four acquired private medical billing companies’ contingent consideration

promissory notes, as more fully described in Note 3, “Debt Obligations” .

We believe that the net proceeds from the

registered direct offerings will be sufficient to fund our operations during the remainder of 2022 and management believes that it now

has adequate liquidity for the foreseeable future from the 2021 registered direct offerings.

However, should those funds not be sufficient,

the Company will explore numerous equity and debt instruments to obtain sufficient funds needed to support its business operations.

believes that it has adequate funding to support its business operations for the foreseeable future as a result of the funds raised through

1 unchanged sentence

cash equivalents:

As of March 31, 2022, we had cash and cash equivalents with an aggregate balance of $20,561,116, a decrease from

a balance of $32,007,792 at December 31, 2021.

Summarized immediately below and discussed in more detail in the subsequent subsections

are the main elements of the $11,446,676 net decrease in cash during the three months ended March 31, 2022:

As of June 30, 2022, we had cash and cash equivalents with an aggregate balance

of $13,454,246, a decrease from a balance of $32,007,792 at December 31, 2021.

Summarized immediately below and discussed in more detail

in the subsequent subsections are the main elements of the $18,553,546 net decrease in cash during the six months ended June 30, 2022:

$10,932,515 of net cash used in operating activities.

cash used in operating activities was $6,055,672 and $3,206,844 for the three months ended March 31, 2022 and 2021, respectively,

an increase of $2,848,828.

The deterioration is attributable to the net loss incurred for the first quarter of 2022, the non-cash

gain attributable to the change in value of the warrant derivative liability, the usage of cash to increase accounts receivable,

prepaid expenses, and other operating assets during the three months ended March 31, 2022 compared to the same period in 2021.

Net cash used in

operating activities was $10,932,515 and $6,149,773 for the six months ended June 30, 2022 and 2021, respectively, an increase of $4,782,742.

The decrease is attributable to the net loss incurred for the first six months of 2022, the non-cash gain attributable to the change in

value of the warrant derivative liability, and the usage of cash to increase accounts receivable, prepaid expenses, and other operating

assets during the six months ended June 30, 2022 compared to the same period in 2021.

$3,361,994 of net cash used in investing activities.

used in investing activities was $3,195,346 and $99,274 for the three months ended March 31, 2022 and 2021, respectively.

During the three months ended March 31, 2022, we made capital expenditures for:

(i) building improvements of the newly

purchased office and warehouse building, and transportation assets;

(ii) patent applications on our proprietary technology

utilized in our new products and included in intangible assets;

and (iii) the closing of a business and asset acquisition.

Cash used in investing

activities was $3,361,994 and $6,506,407 for the six months ended June 30, 2022 and 2021, respectively.

During the six months ended June

30, 2022, we made capital expenditures for:

(i) building improvements of the newly purchased office and warehouse building, and transportation

(ii) patent applications on our proprietary technology utilized in our new products and included in intangible assets;

the closing of a business and asset acquisition.

$4,259,037 of net cash used in financing activities.

Cash used in financing activities was $2,195,658 and cash provided by financing activities

was $66,570,600 for the three months ended March 31, 2022 and 2021, respectively.

During the first three months of 2022 the

Company repurchased its common stock on the open market pursuant to the stock repurchase plan, as well as principal payments

on contingent consideration promissory notes.

During 2021, we raised substantial funds through the completion of two registered

direct offerings of our common stock.

had $20,561,116 of cash and cash equivalents and net positive working capital $19,483,613 as of March 31, 2022.

Cash used in financing

activities was $4,259,037 and cash provided by financing activities was $66,570,600 for the six months ended June 30, 2022 and 2021, respectively.

During the first six months of 2022, the Company repurchased its common stock on the open market pursuant to the stock repurchase plan,

and made principal payments on contingent consideration promissory notes.

During 2021, we raised substantial funds through the completion

of two registered direct offerings of our common stock.

had $13,454,245 of cash and cash equivalents and net positive working capital $15,733,652 as of June 30, 2022.

Accounts receivable and

other receivables balances represented $5,602,094 of our net working capital at March 31, 2022.

We believe we will be able

to collect our outstanding receivables on a timely basis and reduce the overall level during the balance of 2022, which would provide

positive cash flow to support our operations during 2022.

Inventory represents $9,405,920 of our net working capital at March 31, 2022,

and finished goods represented $9,462,527 of total inventory at March 31, 2022.

We are actively managing the level of inventory and our

goal is to reduce such level during the balance of 2022 by our sales activities, the increase of which should provide additional cash

flow to help support our operations during 2022.

other receivables balances represented $4,965,309 of our net working capital at June 30, 2022.

We believe we will be able to collect

our outstanding receivables on a timely basis and reduce the overall level during the balance of 2022, which could provide positive cash

flow to support our operations during 2022.

Inventory represents $9,405,954 of our net working capital at June 30, 2022, and finished

goods represented $9,044,555 of total inventory at June 30, 2022.

We are actively managing the level of inventory and our goal is to

reduce such level during the balance of 2022 by our sales activities, the increase of which should provide additional cash flow to help

support our operations during 2022.

Expenditures:

We had the following material commitments for capital expenditures at March 31, 2022:

had the following material commitments for capital expenditures at June 30, 2022:

Stock Repurchase Program

1 unchanged sentence

outstanding common stock under the specified terms of a share repurchase program (the “Program”).

Subsequent to March 31,

2022, the Company repurchased 1,280,387 shares of its common stock for $1,415,382, in accordance with the Program.

The Program does not

obligate the Company to acquire any specific number of shares and shares may be repurchased in privately negotiated and/or open market

transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the three months

ended June 30, 2022, the Company repurchased 1,849,952 shares of its common stock for $1,962,755, in accordance with the Program.

during the six months ended June 30, 2022, the Company repurchased 3,725,986 shares of its common stock for $4,026,523, in accordance

with the Program.

June 30, 2022, the board of directors of the Company elected to terminate the Program, effective immediately.

The Program began in December

2021, with the Company purchasing a total of 5,460,824 shares at a cost of $6,001,602 through June 30, 2022.

Lease commitments.

following sets forth the operating lease right of use assets and liabilities as of March 31, 2022:

lease expense under the six operating leases was approximately $119,230 and $274,302, during the three and six months ended June 30, 2022,

respectively.

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2022:

following sets forth the operating lease right of use assets and liabilities as of June 30, 2022:

Operating lease right of use assets

2 unchanged sentences

Total operating lease obligations

components of lease expense were as follows for the three months ended March 31, 2022:

Selling, general and administrative expenses

are the minimum lease payments for each year and in total:

Year ending December 31:

2022 (April 1, to December 31, 2022)

2022 (July 1, to December 31, 2022)

Total undiscounted minimum future lease payments

10 unchanged sentences

Debt obligations, long-term

obligations mature as follows as of March 31, 2022:

2022 (April 1, 2022 to December 31, 2022)

obligations mature as follows as of June 30, 2022:

2022 (July 1, 2022 to December 31, 2022)

2027 and thereafter

62 unchanged sentences

Payment is typically due upon delivery of the ticket.

also act as an intermediary between buyers and sellers through the online secondary marketplace.

Revenues derived from this marketplace

primarily consist of service fees from ticketing operations, and consists of one primary performance obligation, which is facilitating

the transaction between the buyer and seller, being satisfied at the time the order has been confirmed.

As we do not control the ticket

prior to the transfer, we act as an agent in these transactions.

Revenue is recognized on a net basis, net of the amount due to the seller

when an order is confirmed, the seller is then obligated to deliver the tickets to the buyer per the seller’s listing.

is due at the time of sale.

We also act as an intermediary

between buyers and sellers through the online secondary marketplace.

Revenues derived from this marketplace primarily consist of service

fees from ticketing operations, and consists of one primary performance obligation, which is facilitating the transaction between the

buyer and seller, being satisfied at the time the order has been confirmed.

As we do not control the ticket prior to the transfer, we

act as an agent in these transactions.

Revenue is recognized on a net basis, net of the amount due to the seller when an order is confirmed.

The seller is then obligated to deliver the tickets to the buyer per the seller’s listing.

Payment is due at the time of sale.

review all significant, unusual, or nonstandard shipments of product or delivery of services as a routine part of our accounting and

10 unchanged sentences

of $248.0 million since we commenced deliveries during 2006.

our ticketing segment, our customers are mainly online visitors that pay at the time of the transaction, and we collect the service fees

charged with the transaction.

Thus, leading to minimal risk for uncollectible accounts, to which we then consider a specific reserve

for bad debts based on their individual circumstances.

As we continue to learn more about the collectability related to this recent acquisition,

we will track historical bad debts and continue to assess appropriate reserves.

For our ticketing segment, our

customers are mainly online visitors that pay at the time of the transaction, and we collect the service fees charged with the transaction,

thus leading to minimal risk for uncollectible accounts, to which we then consider a specific reserve for bad debts based on their individual

circumstances.

As we continue to learn more about the collectability related to this recent acquisition, we will track historical bad

debts and continue to assess appropriate reserves.

our revenue cycle management segment, our customers are mainly medium to large healthcare organizations that are charged monthly upon

12 unchanged sentences

In addition, we adjust the carrying value of inventory if the current market value of that inventory is below its cost.

consisted of the following at March 31, 2022 and December 31, 2021:

consisted of the following at June 30, 2022 and December 31, 2021:

Raw material and component parts– video solutions segment

8 unchanged sentences

As reflected above, our inventory reserves represented

29.3% of the gross inventory balance at March 31, 2022, compared to 28.8% of the gross inventory balance at December 31, 2021.

$3,896,460 and $3,915,089 in reserves for obsolete and excess inventories at March 31, 2022 and December 31, 2021, respectively.

raw materials and component parts were $3,839,796 and $3,062,046 at March 31, 2022 and December 31, 2021, respectively, an increase of

28.4% of the gross inventory balance at June 30, 2022, compared to 28.8% of the gross inventory balance at December 31, 2021.

$3,722,467 and $3,915,089 in reserves for obsolete and excess inventories at June 30, 2022 and December 31, 2021, respectively.

raw materials and component parts were $4,083,713 and $3,062,046 at June 30, 2022 and December 31, 2021, respectively, an increase of

$1,021,667 (33.4%).

Finished goods balances were $9,462,528 and $10,512,579 at March 31, 2022 and December 31, 2021, respectively,

a decrease of $1,050,051 (10%).

The decrease in finished goods was primarily attributable to a reduction in ticketing inventory

of $630,270 at March 31, 2022 compared to December 31, 2021.

The slight decrease in the inventory reserve is primarily due to the reduction

in finished goods that had a reserve placed on them prior to sale.

The remaining reserve for inventory obsolescence is generally provided

for the level of component parts of the older versions of our printed circuit boards and the phase out of our DVM-750, DVM-500 Plus and

LaserAlly legacy products.

Additionally, the Company determined a reasonable reserve for inventory held at the ticket operating segment,

in which some inventory items sell below cost or go unsold, thus having to be fully written-off following the event date.

the reserves are appropriate given our inventory levels at March 31, 2022.

actual future demand or market conditions are less favorable than those projected by management or significant engineering changes to

our products that are not anticipated and appropriately managed, additional inventory write-downs may be required in excess of the inventory

reserves already established.

Finished goods balances were $9,044,555 and $10,512,579 at June 30, 2022 and December 31, 2021, respectively, a decrease

of $1,468,024 (14.0%).

The decrease in finished goods was primarily attributable to a reduction in ticketing inventory of $923,804 at

June 30, 2022 compared to December 31, 2021.

The slight decrease in the inventory reserve is primarily due to the reduction in finished

goods that had a reserve placed on them prior to sale.

The remaining reserve for inventory obsolescence is generally provided for the

level of component parts of the older versions of our printed circuit boards and the phase out of our DVM-750, DVM-500 Plus and LaserAlly

legacy products.

Additionally, the Company determined a reasonable reserve for inventory held at the ticket operating segment, in which

some inventory items sell below cost or go unsold, thus having to be fully written-off following the event date.

We believe the reserves

are appropriate given our inventory levels at June 30, 2022.

actual future demand or market conditions are less favorable than those projected by management or there are significant engineering

changes to our products that are not anticipated and appropriately managed, additional inventory write-downs may be required in

excess of the inventory reserves already established.

and other intangible assets.

30 unchanged sentences

changes in our strategic plans or the use of our assets;

restructuring charges or other changes in our

restructuring changes or other changes in our

business segments;

34 unchanged sentences

quality and minimize claims.

Our warranty reserves were decreased to $10,582 as of March 31, 2022 compared to $13,742 as of December

31, 2021 as we begin to slow our warranty exposures through the roll-off of DVM-750 and DVM-800 units from warranty coverage.

warranty exposure on the DVM-800 and DVM-250plus are the responsibility of the contract manufacturers which reduced our overall warranty

exposure as these are very popular products in our line.

There is a risk that we will have higher warranty claim frequency rates and

average cost of claims than our history has indicated on our legacy mirror products on our new products for which we have limited experience.

Actual experience could differ from the amounts estimated requiring adjustments to these liabilities in future periods.

Our warranty reserves were decreased to $10,582 as of June 30, 2022 compared to $13,742 as of December 31,

2021 as we began to slow our warranty exposures through the roll-off of DVM-750 and DVM-800 units from warranty coverage.

Standard warranty

exposure on the DVM-800 and DVM-250plus are the responsibility of the contract manufacturers which reduced our overall warranty exposure

as these are very popular products in our line.

There is a risk that we will have higher warranty claim frequency rates and average cost

of claims than our history has indicated on our legacy mirror products on our new products for which we have limited experience.

experience could differ from the amounts estimated requiring adjustments to these liabilities in future periods.

derivative liabilities.

9 unchanged sentences

Company has utilized the following assumptions in its Black-Scholes option valuation model to calculate the estimated fair value of the

warrant derivative liabilities as of their date of issuance and as of March 31, 2022:

warrant derivative liabilities as of their date of issuance and as of June 30, 2022:

Issuance date assumptions

March 31, 2022 assumptions

June 30, 2022 assumptions

Volatility - range

12 unchanged sentences

stock-price volatility assumption is based on historical volatilities of the underlying stock that are obtained from public data sources

and there were 25,000 stock options granted during the three months ended March 31, 2022.

and there were 25,000 stock options granted during the six months ended June 30, 2022.

factors change and we develop different assumptions in future periods, the compensation expense that we record in the future may differ

17 unchanged sentences

losses currently recorded and the likelihood that tax positions taken in tax returns will be sustained on audit.

As required by authoritative

guidance, we record deferred tax assets or liabilities based on differences between financial reporting and tax bases of assets and liabilities

using currently enacted rates that will be in effect when the differences are expected to reverse.

Authoritative guidance also requires

that deferred tax assets be reduced by a valuation allowance if it is more likely than not that all or some portion of the deferred tax

asset will not be realized.

As of March 31, 2022, we have fully reserved all of our deferred tax assets.

Based on a review of

our deferred tax assets and recent operating performance, we determined that our valuation allowance should be decreased by $7,615,000

to a balance of $16,980,000 to fully reserve our deferred tax assets at December 31, 2021.

We determined that it was appropriate to continue

to provide a full valuation reserve on our net deferred tax assets as of March 31, 2022, because of the overall net operating

loss carryforwards available.

We expect to continue to maintain a full valuation allowance until we determine that we can sustain a level

of profitability that demonstrates our ability to realize these assets.

To the extent we determine that the realization of some or all

of these benefits is more likely than not based upon expected future taxable income, a portion or all of the valuation allowance will

Such a reversal would be recorded as an income tax benefit and, for some portion related to deductions for stock option

exercises, an increase in shareholders’ equity.

required by authoritative guidance, we record deferred tax assets or liabilities based on differences between financial reporting and

tax bases of assets and liabilities using currently enacted rates that will be in effect when the differences are expected to reverse.

Authoritative guidance also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that

all or some portion of the deferred tax asset will not be realized.

As of June 30, 2022, we have fully reserved all of our deferred tax

Based on a review of our deferred tax assets and recent operating performance, we determined that our valuation allowance should

be decreased by $7,615,000 to a balance of $16,980,000 to fully reserve our deferred tax assets at December 31, 2021.

We determined that

it was appropriate to continue to provide a full valuation reserve on our net deferred tax assets as of June 30, 2022, because of the

overall net operating loss carryforwards available.

We expect to continue to maintain a full valuation allowance until we determine that

we can sustain a level of profitability that demonstrates our ability to realize these assets.

To the extent we determine that the realization

of some or all of these benefits is more likely than not based upon expected future taxable income, a portion or all of the valuation

allowance will be reversed.

Such a reversal would be recorded as an income tax benefit and, for some portion related to deductions for

stock option exercises, an increase in shareholders’ equity.

required by authoritative guidance, we have performed a comprehensive review of our portfolio of uncertain tax positions in accordance

2 unchanged sentences

financial reporting purposes.

We have no recorded liability as of March 31, 2022 representing uncertain tax positions.

We have no recorded liability as of June 30, 2022 representing uncertain tax positions.

have generated substantial deferred income tax assets related to our operations primarily from the charge to compensation expense taken

15 unchanged sentences

and Seasonality

has not materially affected us during the past fiscal year.

We do not believe that our Video Solutions and Revenue Cycle Management

segments business is seasonal in nature, however;

the Ticketing Segment is expected to generate higher revenues during

the second half of the calendar year than in the first half.

As inflation in the United States

and abroad has increased and become more prominent, inflationary pressures adversely affected all of the Company’s reporting segments’

gross margins during the first six months of fiscal year 2022, and are expected to persist for the remainder of fiscal year 2022 and beyond.

We do not believe that our Video Solutions and Revenue Cycle Management segments business is seasonal in nature;

however, the Ticketing

Segment is expected to generate higher revenues during the second half of the calendar year than in the first half due to the increased

sporting events throughout the country during the second half of the calendar year in comparison to the first half.

Quantitative and Qualitative Disclosures about Market Risk.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis